Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 8/20 | 0.59 |
| ▸ | AURKA | O14965 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.59 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 9/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678061 | 0.89 | AURKB (0.64) | AURKBAURKAEGFRINCENPRPS6KB1 | |
| SCHEMBL686666 | 0.82 | AURKB (0.52) | AURKBAURKAEGFRINCENPRPS6KB1 | |
| SCHEMBL26784735 | 0.75 | AURKB (0.60) | AURKBAURKAEGFRINCENPRPS6KB1 | |
| SCHEMBL12306945 | 0.75 | AURKB (0.70) | AURKBAURKAEGFRIRAK4MAPK14 | |
| SCHEMBL26785533 | 0.74 | AURKB (1.00) | AURKBAURKAEGFRINCENPRPS6KB1 | |
| Anilinoquinazoline1 SCHEMBL30195580 | 0.74 | AURKB (1.00) | AURKBAURKAEGFRIRAK4MAPK14 | |
| Anilinoquinazoline1 SCHEMBL1066538 | 0.74 | AURKB (1.00) | AURKBAURKAEGFRIRAK4MAPK14 | |
| Anilinoquinazoline1 SCHEMBL3968007 | 0.74 | AURKB (0.98) | AURKBAURKAEGFRIRAK4MAPK14 | |
| SCHEMBL26785933 | 0.74 | MAPK1 (0.69) | AURKBAURKAEGFRINCENPRPS6KB1 | |
| SCHEMBL3531809 | 0.73 | AURKB (1.00) | AURKBAURKAEGFRIRAK4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | AURKB 3/4885AURKA 1/4885EGFR 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.